What is the recommended regimen for administering iron sucrose 200 mg intravenously each week for five consecutive hemodialysis sessions?

Iron Sucrose 200 mg IV for 5 Doses in Hemodialysis

For hemodialysis patients requiring iron repletion, administer iron sucrose 200 mg intravenously once weekly for 5 consecutive hemodialysis sessions, delivering a total of 1,000 mg over 5 weeks. This regimen effectively corrects iron deficiency while maintaining an excellent safety profile in the dialysis population.

Administration Protocol

Deliver iron sucrose 200 mg as a slow intravenous push over 2–5 minutes directly into the dialysis line, or dilute in 100 mL of 0.9% normal saline and infuse over 30–60 minutes. 1, 2 The FDA approves both rapid push and infusion methods for this dose range. 2

Timing Considerations

• Administer during or immediately after the dialysis session to utilize the existing vascular access and avoid requiring patients to arrive early, which improves adherence. 1
• The 200 mg dose can be safely given over just 2 minutes in chronic kidney disease patients, providing maximum convenience. 2

No Test Dose Required

• Iron sucrose does not require a test dose before administration, unlike iron dextran. 1, 2 However, for patients with a history of IV iron sensitivities or multiple drug allergies, consider a 25 mg test dose given as a slow IV push over 5 minutes, then observe before proceeding with the full dose. 1, 2

Safety Monitoring

Observe all patients for at least 30 minutes after each infusion to detect hypersensitivity reactions. 1, 3 Ensure resuscitation equipment, IV epinephrine, diphenhydramine, and trained personnel are immediately available during administration. 1, 2

Common Adverse Effects

• Hypotension, nausea, vomiting, diarrhea, headache, dizziness, and flushing occur but are typically mild and self-limited. 2
• Hypersensitivity-type reactions occur in approximately 0.5% of patients—significantly lower than iron dextran. 1, 2
• Iron sucrose causes hypophosphatemia in only 1% of patients, compared to 58% with ferric carboxymaltose. 1, 2

Absolute Contraindications

• Do not administer iron sucrose during active bacteremia. 1, 2 Chronic infection alone is not an absolute contraindication if the risk-benefit ratio favors treatment. 2

Expected Clinical Response

Anticipate a hemoglobin increase of 0.9–1.4 g/dL within 4–8 weeks after completing the 5-dose course. 3, 4 Patients with baseline ferritin < 100 ng/mL demonstrate the greatest hemoglobin response (1.4 g/dL increase). 4

Iron Parameter Changes

• Mean serum ferritin increases by approximately 288 ng/mL after the 1,000 mg total dose. 4
• Transferrin saturation increases by an average of 8–10%. 5, 4
• More patients achieve hemoglobin > 11.0 g/dL with IV iron sucrose (54.2%) compared to oral iron (31.3%). 4

Laboratory Monitoring

Check transferrin saturation (TSAT) and serum ferritin 4–8 weeks after the last dose to accurately assess response. 3 Do not measure iron parameters within 7 days after a 200 mg dose, as results will be falsely elevated. 5, 1

Target Iron Parameters

• Maintain TSAT ≥ 20% and serum ferritin ≥ 100 ng/mL to support adequate erythropoiesis. 5, 1, 3
• Withhold further iron if ferritin exceeds 800 ng/mL or TSAT exceeds 50%, as additional hemoglobin gains are unlikely and iron overload risk increases. 1, 3

Transition to Maintenance Therapy

After completing the 5-dose loading regimen (1,000 mg total), transition to maintenance dosing to replace ongoing iron losses from hemodialysis. 5

Maintenance Dosing Options

• Provide 250–1,000 mg of IV iron within each 12-week period, administered weekly, every other week, or with each dialysis session (thrice weekly) according to individual iron losses. 5, 1
• Most hemodialysis patients require ongoing IV iron because oral iron cannot maintain adequate stores due to blood losses averaging 1–3 g of iron annually. 5
• Monitor TSAT and ferritin every 3 months during the maintenance phase. 5, 1

Rationale for This Regimen

The 200 mg weekly × 5 doses regimen delivers the guideline-recommended 1,000 mg total iron load over 8–10 weeks while respecting the maximum safe single dose of 200 mg for iron sucrose. 1, 2 This approach balances efficacy with safety—doses exceeding 200 mg are associated with markedly higher adverse reaction rates. 2

Advantages Over Alternative Regimens

• Weekly dosing is more practical than the older 100 mg twice-weekly regimen, requiring only 5 visits instead of 10. 5
• Iron sucrose 200 mg weekly is as effective as iron dextran 100 mg weekly for 10 weeks but avoids the higher anaphylaxis risk of dextran formulations. 5, 1
• This regimen produces significantly larger increases in ferritin (+243 µg/L) and TSAT (+10.2%) compared to oral iron, while reducing erythropoietin requirements by 20–30%. 1

Common Pitfalls to Avoid

• Do not exceed 200 mg per single dose—higher doses (400–500 mg) dramatically increase adverse reaction rates. 2
• Do not check iron studies too early—wait at least 7 days after the last 200 mg dose to avoid falsely elevated results. 5, 1
• Do not continue iron when ferritin > 800 ng/mL or TSAT > 50%—further administration provides no benefit and risks iron overload. 1, 3
• Do not administer during active infection or bacteremia—this is an absolute contraindication. 1, 2